Medpace Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- August James Troendle
- Full Time Employees
- 6,200
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 5375 Medpace Way Cincinnati OH United States of America 45227
- IPO Date
- Aug 11, 2016
- CIK
- 0001668397
- Website
- medpace.com
- Similar Companies
- Business
- Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries; core offerings encompass clinical trial management, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory services including central laboratories, bioanalytical laboratory, imaging core lab, ECG core lab, and Phase I clinical unit; the company operates its proprietary ClinTrak clinical trial management system to integrate study data and enhance efficiency. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace conducts operations across North America, Europe, Latin America, Asia Pacific, South America, Africa, and Australia, with a focus on complex trials in therapeutic areas such as oncology, cardiology, neurology, and infectious diseases, primarily serving small- to mid-sized biotech clients. In recent developments, the company reported record net new business awards of $789.6 million in Q3 2025, a 47.9% increase year-over-year, driving a net book-to-bill ratio of 1.20 and prompting upward revisions to 2025 revenue guidance to $2.48-$2.53 billion, reflecting 17.6%-20.0% growth over 2024 amid strong backlog momentum exceeding $3 billion; Medpace also projects low double-digit revenue growth and high single-digit EBITDA expansion for 2026, supported by strategic emphases on AI-enabled decentralized trials, oncology, and Phase III studies.
Medpace: Cancellations Are Normalizing
Arrowstreet Capital Limited Partnership Raises Stock Position in Medpace Holdings, Inc. $MEDP
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
Medpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earnings
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace Q2 Earnings Call Highlights
Medpace (MEDP) Beats Q2 Earnings and Revenue Estimates
Medpace Notches A Big Bookings Beat, And Reverses Its First-Quarter Malaise
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
CON vs. MEDP: Which Stock Is the Better Value Option?
Why Medpace (MEDP) Dipped More Than Broader Market Today
A Look at Medpace Holdings Inc (MEDP) After 3.4% Decline -- GF Value $503.39 vs Price $546.29
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026
Medpace Stock Outlook Turns on Backlog Quality and Cancellations
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
CON or MEDP: Which Is the Better Value Stock Right Now?
Medpace (MEDP) Advances While Market Declines: Some Information for Investors
Is It Too Late to Buy Medpace Holdings Inc (MEDP) After 3.9% Rally? GF Value Says Undervalued